Oncology · BiomarkersOtherclinicalmid-term

Circular RNAs as Potential Biomarkers in Cancer Diagnosis and Prognosis

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:34:04 AM

Assessment confidence: 82% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The emerging role of circular RNAs (circRNAs) as potential biomarkers in cancer diagnosis and prognosis represents a significant shift in oncology research. Pharma companies should stay informed about developments in this area to leverage new diagnostic and therapeutic opportunities. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (20 high-relevance).

Strategic Assessment

Pharma companies should explore circRNAs in their R&D pipelines for cancer diagnostics and targeted therapies. The strongest clinical anchor is A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (ClinicalTrials.gov), sponsor/company relevance (merck). In Oncology · Biomarkers, 4 regulatory and 4 competitive items passed relevance filtering for clinical laboratories.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition. The identification of circRNAs as potential biomarkers could shift focus towards novel diagnostic and therapeutic strategies in oncology.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The introduction of circRNAs as biomarkers may necessitate new regulatory pathways for approval, impacting timelines and compliance for diagnostic and therapeutic products.

Key Risks

Elevated medium regulatory exposure for clinical laboratories could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If circRNAs are validated as biomarkers, they could lead to the development of new diagnostic tests and targeted therapies, potentially enhancing market share for companies that adapt their R&D strategies accordingly.
Upside for clinical laboratories may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Upside for clinical laboratories may improve if Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor ongoing research and clinical trials investigating circRNAs in cancer diagnostics and therapeutic applications.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
Humanexa Signalsmedium relevance
Moderate corpus alignment
RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression
Humanexa Signalsmedium relevance
Moderate corpus alignment
New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy
Humanexa Signalsmedium relevance
Moderate corpus alignment

Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Polyploid giant cancer cells: the hidden players in ovarian cancer progression and prognosis.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical laboratories
oncology drug developers
biomarker research firms
cancer treatment centers

Commercial impact

medium

If circRNAs are validated as biomarkers, they could lead to the development of new diagnostic tests and targeted therapies, potentially enhancing market share for companies that adapt their R&D strategies accordingly.

Regulatory impact

medium

The introduction of circRNAs as biomarkers may necessitate new regulatory pathways for approval, impacting timelines and compliance for diagnostic and therapeutic products.

What to watch

Monitor ongoing research and clinical trials investigating circRNAs in cancer diagnostics and therapeutic applications.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.